Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price Target & Predictions
ALNY Stock Forecast
Alnylam Pharmaceuticals stock forecast is as follows: an average price target of $250.16 (represents a -5.70% downside from ALNY’s last price of $265.27) and a rating consensus of 'Buy', based on 21 wall street analysts offering a 1-year stock forecast.
ALNY Price Target
The average price target for Alnylam Pharmaceuticals (ALNY) is $250.16 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $400.00 to $96.00. This represents a potential -5.70% downside from ALNY's last price of $265.27.
ALNY Analyst Ratings
According to 21 Wall Street analysts, Alnylam Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ALNY stock is 0 'Strong Buy' (0.00%), 16 'Buy' (76.19%), 4 'Hold' (19.05%), 1 'Sell' (4.76%), and 0 'Strong Sell' (0.00%).
Alnylam Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 27, 2024 | Kostas Biliouris | BMO Capital | $300.00 | $269.31 | 11.40% | 13.09% |
| Aug 26, 2024 | Luca Issi | RBC Capital | $300.00 | $271.43 | 10.53% | 13.09% |
| Aug 16, 2024 | Salveen Richter | Goldman Sachs | $370.00 | $262.70 | 40.85% | 39.48% |
| Jul 08, 2024 | Whitney Ijem | Canaccord Genuity | $357.00 | $253.86 | 40.63% | 34.58% |
| Jun 28, 2024 | Esther Rajavelu | UBS | $288.00 | $247.00 | 16.60% | 8.57% |
| Jun 27, 2024 | Luca Issi | RBC Capital | $265.00 | $245.17 | 8.09% | -0.10% |
| Jun 27, 2024 | Paul Matteis | Stifel Nicolaus | $295.00 | $247.40 | 19.24% | 11.21% |
| Jun 25, 2024 | Liisa Bayko | Evercore ISI | $260.00 | $222.90 | 16.64% | -1.99% |
| Jun 25, 2024 | Luca Issi | RBC Capital | $250.00 | $222.90 | 12.16% | -5.76% |
| Jun 24, 2024 | Andrew Galler | Morgan Stanley | $250.00 | $224.70 | 11.26% | -5.76% |
The latest Alnylam Pharmaceuticals stock forecast, released on Aug 27, 2024 by Kostas Biliouris from BMO Capital, set a price target of $300.00, which represents a 11.40% increase from the stock price at the time of the forecast ($269.31), and a 13.09% increase from ALNY last price ($265.27).
Alnylam Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 3 | 12 | 14 |
| Avg Price Target | $323.33 | $298.50 | $289.36 |
| Last Closing Price | $265.27 | $265.27 | $265.27 |
| Upside/Downside | 21.89% | 12.53% | 9.08% |
In the current month, the average price target of Alnylam Pharmaceuticals stock is $323.33, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 21.89% increase as opposed to Alnylam Pharmaceuticals's last price of $265.27. This month's average price target is up 8.32% compared to last quarter, and up 11.74% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | Oppenheimer | Perform | Perform | Hold |
| Sep 03, 2024 | Wolfe Research | Negative | Negative | Hold |
| Sep 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 03, 2024 | Barclays | Overweight | Overweight | Hold |
| Aug 27, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 26, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Aug 16, 2024 | Goldman Sachs | Neutral | Buy | Upgrade |
| Aug 02, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Aug 02, 2024 | Barclays | Overweight | Overweight | Hold |
Alnylam Pharmaceuticals's last stock rating was published by Oppenheimer on Sep 03, 2024. The company gave ALNY a "Perform" rating, the same as its previous rate.
Alnylam Pharmaceuticals Financial Forecast
Alnylam Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $750.53M | - | $319.29M | $335.04M | $264.31M | - | $213.26M | $258.54M | $187.63M | $220.55M | $177.57M | $163.56M | $125.85M | $103.96M | $99.48M | $71.68M | $70.06M |
| Avg Forecast | $947.97M | $898.63M | $774.48M | $730.99M | $756.71M | $654.76M | $572.26M | $544.45M | $554.21M | $527.81M | $447.22M | $428.01M | $436.92M | $396.76M | $332.28M | $312.27M | $313.13M | $291.66M | $255.56M | $240.95M | $233.61M | $218.72M | $192.05M | $168.50M | $146.64M | $119.05M | $98.76M | $91.74M | $71.60M | $57.17M |
| High Forecast | $1.05B | $996.51M | $858.84M | $810.61M | $839.13M | $726.07M | $634.58M | $603.75M | $614.57M | $580.76M | $495.93M | $474.62M | $483.30M | $647.63M | $368.47M | $346.28M | $347.24M | $323.42M | $255.56M | $271.95M | $263.67M | $246.86M | $216.77M | $190.18M | $165.51M | $134.37M | $111.47M | $103.55M | $80.81M | $64.53M |
| Low Forecast | $825.41M | $782.46M | $674.36M | $636.49M | $658.89M | $570.11M | $498.28M | $474.06M | $482.56M | $499.51M | $389.40M | $372.67M | $371.99M | $327.97M | $289.32M | $271.90M | $272.65M | $253.95M | $255.56M | $226.57M | $219.67M | $205.67M | $180.59M | $158.45M | $137.89M | $111.95M | $92.87M | $86.27M | $67.33M | $53.76M |
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 13 | 6 | 7 | 12 | 7 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.89% | - | 1.02% | 1.07% | 0.91% | - | 0.89% | 1.11% | 0.86% | 1.15% | 1.05% | 1.12% | 1.06% | 1.05% | 1.08% | 1.00% | 1.23% |
Alnylam Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 11 analysts is $436.92M, with a low forecast of $371.99M, and a high forecast of $483.30M. ALNY's average Quarter revenue forecast represents a -41.79% decrease compared to the company's last Quarter revenue of $750.53M (Sep 23).
Alnylam Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 13 | 6 | 7 | 12 | 7 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $213.87M | - | $-143.41M | $-177.11M | $-234.69M | - | $-142.59M | $-202.03M | $-140.74M | $-132.75M | $-143.90M | $-194.20M | $-204.95M | $-132.88M | $-159.16M | $-254.57M | $-181.39M |
| Avg Forecast | $-725.55M | $-687.79M | $-592.77M | $-559.48M | $-579.17M | $-501.13M | $-437.99M | $-416.70M | $-424.18M | $-403.97M | $-342.29M | $-207.18M | $-334.40M | $-303.67M | $-254.31M | $-188.35M | $-239.66M | $-151.40M | $-195.60M | $-171.23M | $-291.55M | $-137.64M | $-139.46M | $-155.94M | $-166.32M | $-147.75M | $-157.19M | $-188.16M | $-232.34M | $-202.53M |
| High Forecast | $-631.75M | $-598.87M | $-516.13M | $-487.15M | $-504.29M | $-436.35M | $-381.37M | $-362.83M | $-369.34M | $-382.31M | $-298.04M | $-165.75M | $-284.71M | $-251.02M | $-221.44M | $-150.68M | $-208.68M | $-121.12M | $-195.60M | $-136.98M | $-233.24M | $-110.11M | $-111.57M | $-124.75M | $-133.05M | $-118.20M | $-125.75M | $-150.53M | $-185.87M | $-162.02M |
| Low Forecast | $-804.57M | $-762.70M | $-657.33M | $-620.42M | $-642.25M | $-555.72M | $-485.69M | $-462.09M | $-470.38M | $-444.50M | $-379.57M | $-248.62M | $-369.90M | $-495.67M | $-282.01M | $-226.02M | $-265.77M | $-181.68M | $-195.60M | $-205.47M | $-349.86M | $-165.16M | $-167.36M | $-187.13M | $-199.58M | $-177.30M | $-188.63M | $-225.79M | $-278.80M | $-243.04M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.70% | - | 0.76% | 0.74% | 1.55% | - | 0.83% | 0.69% | 1.02% | 0.95% | 0.92% | 1.17% | 1.39% | 0.85% | 0.85% | 1.10% | 0.90% |
11 analysts predict ALNY's average Quarter EBITDA for Dec 23 to be $-334.40M, with a high of $-284.71M and a low of $-369.90M. This is -256.36% lower than Alnylam Pharmaceuticals's previous annual EBITDA (Sep 23) of $213.87M.
Alnylam Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 13 | 6 | 7 | 12 | 7 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $147.75M | - | $-174.10M | $-207.49M | $-405.92M | - | $-240.34M | $-258.46M | $-204.51M | $-189.56M | $-200.29M | $-243.54M | $-253.29M | $-179.23M | $-182.22M | $-276.19M | $-208.53M |
| Avg Forecast | $100.69M | $93.16M | $22.39M | $2.83M | $1.87M | $-66.35M | $-102.77M | $-105.18M | $-110.11M | $-115.01M | $-135.23M | $-265.52M | $-150.35M | $-183.21M | $-190.84M | $-241.39M | $-235.63M | $-203.47M | $-199.94M | $-219.44M | $-150.86M | $-184.97M | $-184.73M | $-202.61M | $-197.88M | $-173.95M | $-197.77M | $-208.25M | $-245.08M | $-220.80M |
| High Forecast | $114.95M | $106.35M | $25.56M | $3.23M | $2.14M | $-55.20M | $-85.50M | $-87.50M | $-91.60M | $-43.70M | $-112.50M | $-212.42M | $6.26M | $90.26M | $-158.77M | $-193.11M | $-196.03M | $-162.78M | $-199.94M | $-175.55M | $-120.68M | $-147.98M | $-147.78M | $-162.09M | $-158.30M | $-139.16M | $-158.22M | $-166.60M | $-196.07M | $-176.64M |
| Low Forecast | $83.77M | $77.50M | $18.63M | $2.35M | $1.56M | $-75.74M | $-117.32M | $-120.07M | $-125.70M | $-163.31M | $-154.37M | $-318.63M | $-385.90M | $-261.35M | $-217.87M | $-289.66M | $-268.99M | $-244.17M | $-199.94M | $-263.33M | $-181.03M | $-221.97M | $-221.68M | $-243.13M | $-237.45M | $-208.74M | $-237.32M | $-249.90M | $-294.10M | $-264.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.81% | - | 0.72% | 0.88% | 1.99% | - | 1.10% | 1.71% | 1.11% | 1.03% | 0.99% | 1.23% | 1.46% | 0.91% | 0.88% | 1.13% | 0.94% |
Alnylam Pharmaceuticals's average Quarter net income forecast for Dec 23 is $-150.35M, with a range of $-385.90M to $6.26M. ALNY's average Quarter net income forecast represents a -201.76% decrease compared to the company's last Quarter net income of $147.75M (Sep 23).
Alnylam Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 13 | 6 | 7 | 12 | 7 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $199.18M | - | $183.66M | $210.34M | $235.86M | - | $154.47M | $186.38M | $142.07M | $145.32M | $146.86M | $166.29M | $167.47M | $127.90M | $126.76M | $156.28M | $120.35M |
| Avg Forecast | $1.00B | $950.18M | $818.91M | $772.93M | $800.12M | $692.32M | $605.08M | $575.68M | $586.00M | $558.08M | $472.88M | $170.66M | $461.98M | $419.52M | $351.34M | $155.14M | $331.10M | $141.35M | $270.22M | $141.04M | $108.79M | $128.50M | $141.62M | $148.56M | $135.11M | $115.01M | $104.43M | $97.00M | $75.71M | $60.45M |
| High Forecast | $1.11B | $1.05B | $908.10M | $857.11M | $887.27M | $767.73M | $670.99M | $638.38M | $649.83M | $614.07M | $524.38M | $204.79M | $511.02M | $684.78M | $389.60M | $186.17M | $367.16M | $169.62M | $270.22M | $169.25M | $130.54M | $154.20M | $169.94M | $178.27M | $162.13M | $138.01M | $117.87M | $109.49M | $85.45M | $68.23M |
| Low Forecast | $872.77M | $827.35M | $713.04M | $673.00M | $696.68M | $602.82M | $526.86M | $501.26M | $510.25M | $528.17M | $411.74M | $136.53M | $393.33M | $346.78M | $305.92M | $124.11M | $288.29M | $113.08M | $270.22M | $112.83M | $87.03M | $102.80M | $113.30M | $118.85M | $108.09M | $92.01M | $98.20M | $91.22M | $71.19M | $56.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.47% | - | 1.18% | 0.64% | 1.67% | - | 1.10% | 1.71% | 1.11% | 1.03% | 0.99% | 1.23% | 1.46% | 1.22% | 1.31% | 2.06% | 1.99% |
Alnylam Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $461.98M, based on 11 Wall Street analysts, with a range of $393.33M to $511.02M. The forecast indicates a 131.95% rise compared to ALNY last annual SG&A of $199.18M (Sep 23).
Alnylam Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 13 | 6 | 7 | 12 | 7 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.18 | - | $-1.40 | $-1.68 | $-3.32 | - | $-2.00 | $-2.16 | $-1.72 | $-1.61 | $-1.71 | $-2.09 | $-2.18 | $-1.56 | $-1.62 | $-2.47 | $-1.92 |
| Avg Forecast | $0.79 | $0.74 | $0.18 | $0.02 | $0.01 | $-0.52 | $-0.81 | $-0.83 | $-0.87 | $-0.91 | $-1.07 | $-1.12 | $-1.19 | $-1.45 | $-1.51 | $-1.67 | $-1.86 | $-1.74 | $-1.59 | $-1.81 | $-1.55 | $-1.54 | $-1.61 | $-1.75 | $-1.78 | $-1.63 | $-1.72 | $-1.89 | $-2.21 | $-2.07 |
| High Forecast | $0.91 | $0.84 | $0.20 | $0.03 | $0.02 | $-0.44 | $-0.67 | $-0.69 | $-0.72 | $-0.34 | $-0.89 | $-0.93 | $0.05 | $0.71 | $-1.25 | $-1.39 | $-1.55 | $-1.45 | $-1.59 | $-1.67 | $-1.43 | $-1.42 | $-1.48 | $-1.61 | $-1.64 | $-1.50 | $-1.59 | $-1.74 | $-2.04 | $-1.91 |
| Low Forecast | $0.66 | $0.61 | $0.15 | $0.02 | $0.01 | $-0.60 | $-0.93 | $-0.95 | $-0.99 | $-1.29 | $-1.22 | $-1.27 | $-3.04 | $-2.06 | $-1.72 | $-1.91 | $-2.12 | $-1.99 | $-1.59 | $-2.11 | $-1.80 | $-1.79 | $-1.87 | $-2.04 | $-2.08 | $-1.90 | $-2.01 | $-2.20 | $-2.58 | $-2.42 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.82% | - | 0.84% | 0.90% | 1.90% | - | 1.11% | 1.40% | 1.12% | 1.00% | 0.98% | 1.17% | 1.34% | 0.90% | 0.86% | 1.12% | 0.93% |
According to 11 Wall Street analysts, Alnylam Pharmaceuticals's projected average Quarter EPS for Dec 23 is $-1.19, with a low estimate of $-3.04 and a high estimate of $0.05. This represents a -200.54% decrease compared to ALNY previous annual EPS of $1.18 (Sep 23).
Alnylam Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| WVE | Wave Life Sciences | $5.86 | $14.00 | 138.91% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| PRQR | ProQR Therapeutics | $1.85 | $3.63 | 96.22% | Buy |
| RARE | Ultragenyx Pharmaceutical | $58.74 | $108.14 | 84.10% | Buy |
| BMRN | BioMarin Pharmaceutical | $84.90 | $111.41 | 31.22% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| INCY | Incyte | $63.56 | $81.00 | 27.44% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| EXEL | Exelixis | $26.46 | $28.00 | 5.82% | Buy |
| KRYS | Krystal Biotech | $201.58 | $191.00 | -5.25% | Buy |
| ALNY | Alnylam Pharmaceuticals | $265.27 | $250.16 | -5.70% | Buy |
| UTHR | United Therapeutics | $339.12 | $312.50 | -7.85% | Buy |
| HALO | Halozyme Therapeutics | $62.30 | $56.86 | -8.73% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
ALNY Forecast FAQ
Is Alnylam Pharmaceuticals a good buy?
Yes, according to 21 Wall Street analysts, Alnylam Pharmaceuticals (ALNY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 16 'Buy' recommendations, accounting for 76.19% of ALNY's total ratings.
What is ALNY's price target?
Alnylam Pharmaceuticals (ALNY) average price target is $250.16 with a range of $96 to $400, implying a -5.70% from its last price of $265.27. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Alnylam Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for ALNY stock, the company can go down by -5.70% (from the last price of $265.27 to the average price target of $250.16), up by 50.79% based on the highest stock price target, and down by -63.81% based on the lowest stock price target.
Can Alnylam Pharmaceuticals stock reach $400?
ALNY's average twelve months analyst stock price target of $250.16 does not support the claim that Alnylam Pharmaceuticals can reach $400 in the near future.
What is Alnylam Pharmaceuticals's current price target trend?
3 Wall Street analysts forecast a $323.33 price target for Alnylam Pharmaceuticals (ALNY) this month, up 21.89% from its last price of $265.27. Compared to the last 3 and 12 months, the average price target increased by 12.53% and increased by 9.08%, respectively.
What are Alnylam Pharmaceuticals's analysts' financial forecasts?
Alnylam Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.53B (high $2.8B, low $2.2B), average EBITDA is $-1.935B (high $-1.685B, low $-2.146B), average net income is $-272M (high $-226M, low $-312M), average SG&A $2.67B (high $2.96B, low $2.33B), and average EPS is $-2.15 (high $-1.784, low $-2.459). ALNY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.35B (high $3.72B, low $2.92B), average EBITDA is $-2.566B (high $-2.234B, low $-2.845B), average net income is $219.07M (high $250.09M, low $182.25M), average SG&A $3.54B (high $3.93B, low $3.09B), and average EPS is $1.73 (high $1.97, low $1.44).
Did the ALNY's actual financial results beat the analysts' financial forecasts?
Based on Alnylam Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $1.83B, beating the average analysts forecast of $1.48B by 23.68%. Apple's EBITDA was $-282M, missing the average prediction of $-1.081B by -73.89%. The company's net income was $-440M, missing the average estimation of $-766M by -42.51%. Apple's SG&A was $0, missing the average forecast of $1.39B by -100.00%. Lastly, the company's EPS was $0, missing the average prediction of $-5.808 by -100.00%. In terms of the last quarterly report (Sep 2023), Alnylam Pharmaceuticals's revenue was $750.53M, beating the average analysts' forecast of $396.76M by 89.17%. The company's EBITDA was $213.87M, missing the average prediction of $-304M by -170.43%. Alnylam Pharmaceuticals's net income was $147.75M, missing the average estimation of $-183M by -180.65%. The company's SG&A was $199.18M, missing the average forecast of $419.52M by -52.52%. Lastly, the company's EPS was $1.18, missing the average prediction of $-1.446 by -181.62%